DUBLIN and SAN FRANCISCO – May 10, 2019 – Three new studies show that patients who are medically indicated for implantable heart devices, including implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT), often do not receive needed therapy. The findings underscore gender and race treatment disparities, as well as a […]
Tag: Medtronic
Philips announces collaboration with Medtronic to further advance the image-guided treatment of atrial fibrillation
May 9, 2019 Philips’ integrated solution will combine the unique KODEX-EPD dielectric imaging and navigation system, dielectric imaging sensors, clinical software, and services to support cryoablation procedures performed with the Medtronic Arctic Front Advance™ cryoablation technology Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced a collaboration with Medtronic to further advance […]
Medtronic Receives FDA Approval for CareLink SmartSync Device Manager
DUBLIN – May 2, 2019 – Medtronic plc (NYSE:MDT) today announced that the company has received U.S. Food and Drug Administration (FDA) approval for the CareLink SmartSync(TM) Device Manager. With the introduction of SmartSync, physicians will now be able to use an Apple® iPad® to program and manage data from Medtronic’s BlueSync-enabled […]
Medtronic Receives FDA Approval for World’s First Quadripolar Active Fixation Left Heart Lead
DUBLIN – May 1, 2019 – Medtronic plc (NYSE:MDT) announced it has received U.S. Food and Drug Administration (FDA) approval for the Attain Stability(TM) Quad MRI SureScan(TM) left heart lead. Paired with Medtronic quadripolar cardiac resynchronization therapy-defibrillators (CRT-D) and -pacemakers (CRT-P), the Attain Stability Quad lead is the only active-fixation left […]
Medtronic Announces U.S. Commercial Launch of Solitaire(TM) X Revascularization Device
DUBLIN – April 30, 2019 – Medtronic plc (NYSE:MDT) today announced the U.S. launch of the Solitaire(TM) X Revascularization Device – and its first use in patients for the treatment of acute ischemic stroke. For ten years, the industry-leading Solitaire(TM) Revascularization Device has enabled physicians in helping patients have a better […]
Medtronic HeartWare(TM) HVAD(TM) System Demonstrates Reduction in Total Strokes, Disabling Strokes and Stroke-Related Mortality with Blood Pressure Management
DUBLIN and ORLANDO, Fla. – April 5, 2019 – Medtronic plc (NYSE:MDT) today announced the results of an analysis on the impact of stroke severity in patients receiving its HeartWare(TM) HVAD(TM) System as destination therapy, showing that targeted blood pressure management helped reduce serious strokes. The HVAD System is a left […]
Medtronic Announces the Upsizing of its Maximum Tender Offers for Certain Outstanding Debt Securities Issued by Medtronic, Inc. and Covidien International Finance S.A.
DUBLIN – March 4, 2019 – Medtronic plc (the “Company”) (NYSE:MDT) today announced the upsizing of the previously-announced cash tender offers by its wholly-owned subsidiaries, Medtronic, Inc. and Covidien International Finance S.A. (“CIFSA” and, together with Medtronic, Inc., the “Offerors”) for up to $1.9 billion combined aggregate purchase price (excluding accrued […]
Medtronic Resolute(TM) Drug-Eluting Stent (DES) Platform Receives Expanded Indication for Treatment of Chronic Total Occlusion (CTO)
DUBLIN – February 26, 2019 – Medtronic plc (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval of its Resolute Drug-Eluting Stent (DES) platform (including the Resolute Onyx(TM) and Resolute Integrity(TM) DES) for the treatment of patients with coronary artery disease who have de novo chronic total occlusion (CTO), a complex […]
Medtronic Reports Third Quarter Financial Results
DUBLIN – February 19, 2019 – Medtronic plc (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2019, which ended January 25, 2019. The company reported third quarter worldwide revenue of $7.546 billion, an increase of 2.4 percent as reported or 4.4 percent on an organic basis, […]
Medtronic Receives FDA Approval on Expanded Indication for Pipeline Flex Embolization Device
DUBLIN – February 7, 2019 – Medtronic plc (NYSE:MDT) announced today that it has received U.S. Food and Drug Administration (FDA) approval on an expanded indication for its Pipeline(TM) Flex embolization device.1 Previously indicated for the endovascular treatment of adults with large or giant wide-necked intracranial aneurysms (IAs) in the internal carotid […]
Recent
Rad AI Appoints Chief Operating Officer and First Chief Clinical Officer, Strengthening Operational and Clinical Strategy
Adagio Medical to Participate in the BofA Securities 2026 Health Care Conference
BD Reimagines Central Line Insertion, Advancing Leadership in Patient Safety Through Breakthrough Vascular Access Technology
Popular
- No commented posts yet